Mirogabalin and emerging therapies for diabetic neuropathy

Saad Javed, Uazman Alam, Rayaz Malik

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

There are currently no approved disease-modifying therapies for diabetic neuropathy, and there are only 3 US Food and Drug Administration-approved therapies (pregabalin, duloxetine, and tapentadol) for painful diabetic neuropathy. They each have moderate efficacy with adverse effects limiting optimal dose titration. There is a considerable need for new therapies for the management of painful diabetic neuropathy. We reviewed the potential role of mirogabalin, which like gabapentin and pregabalin modulates the alpha-2/delta-1 subunit of the voltage-gated calcium channel, allowing the influx of calcium and release of neurotransmitters at the synaptic cleft in the central nervous system and spinal cord. It has shown efficacy and good tolerability in a Phase II study in diabetic painful neuropathy and based on the results of two Phase III clinical trials in diabetic painful neuropathy and post-herpetic neuralgia, Daiichi Sankyo submitted a marketing application for neuropathic pain in Japan in February 2018. We have also reviewed potential new therapies, currently in Phase II clinical trials that may modify disease and/or relieve neuropathic pain through novel modes of action.

Original languageEnglish
Pages (from-to)1559-1566
Number of pages8
JournalJournal of Pain Research
Volume11
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Diabetic Neuropathies
Neuralgia
Therapeutics
Phase III Clinical Trials
Phase II Clinical Trials
United States Food and Drug Administration
Calcium Channels
Marketing
Neurotransmitter Agents
Spinal Cord
Japan
Central Nervous System
mirogabalin
Calcium
Pregabalin

Keywords

  • Diabetic neuropathy
  • Mirogabalin
  • Painful diabetic neuropathy
  • Treatment

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Mirogabalin and emerging therapies for diabetic neuropathy. / Javed, Saad; Alam, Uazman; Malik, Rayaz.

In: Journal of Pain Research, Vol. 11, 01.01.2018, p. 1559-1566.

Research output: Contribution to journalReview article

Javed, Saad ; Alam, Uazman ; Malik, Rayaz. / Mirogabalin and emerging therapies for diabetic neuropathy. In: Journal of Pain Research. 2018 ; Vol. 11. pp. 1559-1566.
@article{6ff1396cc36f4cd88a915c30e725f9f2,
title = "Mirogabalin and emerging therapies for diabetic neuropathy",
abstract = "There are currently no approved disease-modifying therapies for diabetic neuropathy, and there are only 3 US Food and Drug Administration-approved therapies (pregabalin, duloxetine, and tapentadol) for painful diabetic neuropathy. They each have moderate efficacy with adverse effects limiting optimal dose titration. There is a considerable need for new therapies for the management of painful diabetic neuropathy. We reviewed the potential role of mirogabalin, which like gabapentin and pregabalin modulates the alpha-2/delta-1 subunit of the voltage-gated calcium channel, allowing the influx of calcium and release of neurotransmitters at the synaptic cleft in the central nervous system and spinal cord. It has shown efficacy and good tolerability in a Phase II study in diabetic painful neuropathy and based on the results of two Phase III clinical trials in diabetic painful neuropathy and post-herpetic neuralgia, Daiichi Sankyo submitted a marketing application for neuropathic pain in Japan in February 2018. We have also reviewed potential new therapies, currently in Phase II clinical trials that may modify disease and/or relieve neuropathic pain through novel modes of action.",
keywords = "Diabetic neuropathy, Mirogabalin, Painful diabetic neuropathy, Treatment",
author = "Saad Javed and Uazman Alam and Rayaz Malik",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/JPR.S145999",
language = "English",
volume = "11",
pages = "1559--1566",
journal = "Journal of Pain Research",
issn = "1178-7090",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Mirogabalin and emerging therapies for diabetic neuropathy

AU - Javed, Saad

AU - Alam, Uazman

AU - Malik, Rayaz

PY - 2018/1/1

Y1 - 2018/1/1

N2 - There are currently no approved disease-modifying therapies for diabetic neuropathy, and there are only 3 US Food and Drug Administration-approved therapies (pregabalin, duloxetine, and tapentadol) for painful diabetic neuropathy. They each have moderate efficacy with adverse effects limiting optimal dose titration. There is a considerable need for new therapies for the management of painful diabetic neuropathy. We reviewed the potential role of mirogabalin, which like gabapentin and pregabalin modulates the alpha-2/delta-1 subunit of the voltage-gated calcium channel, allowing the influx of calcium and release of neurotransmitters at the synaptic cleft in the central nervous system and spinal cord. It has shown efficacy and good tolerability in a Phase II study in diabetic painful neuropathy and based on the results of two Phase III clinical trials in diabetic painful neuropathy and post-herpetic neuralgia, Daiichi Sankyo submitted a marketing application for neuropathic pain in Japan in February 2018. We have also reviewed potential new therapies, currently in Phase II clinical trials that may modify disease and/or relieve neuropathic pain through novel modes of action.

AB - There are currently no approved disease-modifying therapies for diabetic neuropathy, and there are only 3 US Food and Drug Administration-approved therapies (pregabalin, duloxetine, and tapentadol) for painful diabetic neuropathy. They each have moderate efficacy with adverse effects limiting optimal dose titration. There is a considerable need for new therapies for the management of painful diabetic neuropathy. We reviewed the potential role of mirogabalin, which like gabapentin and pregabalin modulates the alpha-2/delta-1 subunit of the voltage-gated calcium channel, allowing the influx of calcium and release of neurotransmitters at the synaptic cleft in the central nervous system and spinal cord. It has shown efficacy and good tolerability in a Phase II study in diabetic painful neuropathy and based on the results of two Phase III clinical trials in diabetic painful neuropathy and post-herpetic neuralgia, Daiichi Sankyo submitted a marketing application for neuropathic pain in Japan in February 2018. We have also reviewed potential new therapies, currently in Phase II clinical trials that may modify disease and/or relieve neuropathic pain through novel modes of action.

KW - Diabetic neuropathy

KW - Mirogabalin

KW - Painful diabetic neuropathy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85058779425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058779425&partnerID=8YFLogxK

U2 - 10.2147/JPR.S145999

DO - 10.2147/JPR.S145999

M3 - Review article

AN - SCOPUS:85058779425

VL - 11

SP - 1559

EP - 1566

JO - Journal of Pain Research

JF - Journal of Pain Research

SN - 1178-7090

ER -